SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Li, Y.-P. Articles by Gallagher, R. E. Search for Related Content PubMed PubMed Citation Articles by Li, Y.-P. Articles by Gallagher, R. E. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  RAR1/RAR2-PML mRNA Expression in Acute Promyelocytic Leukemia Cells: A Molecular and Laboratory-Clinical Correlative Study Yun-Ping Li, Janet Andersen, Arthur Zelent, Sreenivas Rao, Elisabeth Paietta, Martin S. Tallman, Peter H. Wiernik, and Robert E. Gallagher From the Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY; the Dana Farber Cancer Institute, Boston, MA; the Northwestern University Medical School, Chicago, IL; and the Leukaemia Research Fund, London, UK. In addition to the major fusion gene PML-RAR, the t(15; 17) in acute promyelocytic leukemia (APL) produces the reciprocal fusion gene RAR-PML. To determine the scope of RAR-containing mRNA expression in APL cells, we tested PML-RAR-positive APL cells for the presence of mRNAs initiated from two distinct RAR gene promoters, 1 and 2. From the normal allele, both RAR1 and RAR2 mRNAs were expressed in all APL cases (N = 24). From the translocated allele, RAR1-PML mRNA was expressed in 77% and RAR2-PML mRNA in 28% of cases (N = 98). RAR2-PML mRNA was not observed in the absence of RAR1-PML mRNA. There was no association between RAR1-PML or RAR2-PML mRNA expression and the type of PML-RAR mRNA formed by either 5' or 3' breaksites in the PML gene. RAR1-PML mRNAs and RAR2-PML mRNAs from 5' PML breaksite cases coded for full-length RAR-PML proteins but RAR2-PML mRNAs from 3' PML breaksite cases encoded a truncated RAR2 peptide. RAR1/2-PML mRNA expression was not associated with differences in APL cell sensitivity to all-trans retinoic acid(tRA)-induced differentiation in vitro or in clinical outcome after tRA or chemotherapy induction therapy (protocol E2491). Our analysis indicated that RAR1/2-PML mRNA expression markedly differs from normal RAR1/2 mRNA expression, that the difference in RAR1-PML and RAR2-PML mRNA expression frequency is primarily related to the genomic separation of the RAR1 and RAR2 coding exons, and that variations in RAR1/2-PML mRNA expression likely have no clinically relevant function in APL cells. Blood, Vol. 90 No. 1 (July 1), 1997: pp. 306-312 © 1997 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. J. Walter, R. E. Ries, J. R. Armstrong, J. S. Park, E. R. Mardis, and T. J. Ley Expression of a bcr-1 isoform of RAR{alpha}-PML does not affect the penetrance of acute promyelocytic leukemia or the acquisition of an interstitial deletion on mouse chromosome 2 Blood, February 1, 2007; 109(3): 1237 - 1240. [Abstract] [Full Text] [PDF] Y. Jing, N. Hellinger, L. Xia, A. Monks, E. A. Sausville, A. Zelent, and S. Waxman Benzodithiophenes Induce Differentiation and Apoptosis in Human Leukemia Cells Cancer Res., September 1, 2005; 65(17): 7847 - 7855. [Abstract] [Full Text] [PDF] X.-f. Wang, D. Z. Qian, M. Ren, Y. Kato, Y. Wei, L. Zhang, Z. Fansler, D. Clark, O. Nakanishi, and R. Pili Epigenetic Modulation of Retinoic Acid Receptor {beta}2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3535 - 3542. [Abstract] [Full Text] [PDF] E. F. Farias, A. Arapshian, I. J. Bleiweiss, S. Waxman, A. Zelent, and R. Mira-y-Lopez Retinoic Acid Receptor {alpha}2 Is a Growth Suppressor Epigenetically Silenced In MCF-7 Human Breast Cancer Cells Cell Growth Differ., August 1, 2002; 13(8): 335 - 341. [Abstract] [Full Text] [PDF] D. B. Zimonjic, J. L. Pollock, P. Westervelt, N. C. Popescu, and T. J. Ley Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice PNAS, November 21, 2000; 97(24): 13306 - 13311. [Abstract] [Full Text] [PDF] J. L. Pollock, P. Westervelt, A. K. Kurichety, P. G. Pelicci, J. L. Grisolano, and T. J. Ley A bcr-3 isoform of RARalpha -PML potentiates the development of PML-RARalpha -driven acute promyelocytic leukemia PNAS, December 21, 1999; 96(26): 15103 - 15108. [Abstract] [Full Text] [PDF] A. Melnick and J. D. Licht Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia Blood, May 15, 1999; 93(10): 3167 - 3215. [Full Text] [PDF] C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome? J. Clin. Oncol., January 1, 1999; 17(1): 293 - 293. [Abstract] [Full Text] [PDF] W. Ding, Y.-P. Li, L. M. Nobile, G. Grills, I. Carrera, E. Paietta, M. S. Tallman, P. H. Wiernik, and R. E. Gallagher Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RARalpha Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy Blood, August 15, 1998; 92(4): 1172 - 1183. [Abstract] [Full Text] [PDF]

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020